Cargando…
Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer
There are currently no molecular targeted approaches to treat small-cell lung cancer (SCLC) similar to those used successfully against non-small-cell lung cancer. This failure is attributable to our inability to identify clinically-relevant subtypes of this disease. Thus, a more systematic approach...
Autores principales: | Wildey, Gary, Chen, Yanwen, Lent, Ian, Stetson, Lindsay, Pink, John, Barnholtz-Sloan, Jill S., Dowlati, Afshin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157793/ https://www.ncbi.nlm.nih.gov/pubmed/25198282 http://dx.doi.org/10.1371/journal.pone.0106784 |
Ejemplares similares
-
RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
por: Sakre, Nneha, et al.
Publicado: (2016) -
Computational identification of multi-omic correlates of anticancer therapeutic response
por: Stetson, Lindsay C, et al.
Publicado: (2014) -
Erratum: Computational identification of multi-omic correlates of anticancer therapeutic response
por: Stetson, Lindsay C, et al.
Publicado: (2015) -
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
por: Lindner, Daniel J., et al.
Publicado: (2020) -
PIAS3 expression in squamous cell lung cancer is low and predicts overall survival
por: Abbas, Rime, et al.
Publicado: (2015)